BILLERICA, Mass., March 2, 2016 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced the promotion of Shacey Petrovic to the newly-created role of President, Insulet Diabetes Products and the recent appointment of Charles Alpuche as Senior Vice President of Global Manufacturing and Operations.
As President, Insulet Diabetes Products, Ms. Petrovic will lead the Company's global growth initiatives within the diabetes business, including cross-functional integration, financial investments and achievement of all operating targets and will continue to oversee sales, marketing, managed care, customer care and strategic partnerships.
In his role as Senior Vice President of Global Manufacturing and Operations, Mr. Alpuche is responsible for Insulet's global manufacturing and operations teams with a focus on the Company's global manufacturing footprint and identifying opportunities to significantly improve manufacturing operations and supply chain effectiveness.
"We are very pleased to recognize Shacey's important contributions to our organization," said Patrick Sullivan, President and Chief Executive Officer. "Since joining Insulet one year ago as Chief Commercial Officer, Shacey has led the successful re-alignment of all of our commercial operations. Under her leadership, Insulet achieved record-breaking commercial results, reset the product development roadmap and established an energized and collaborative culture."
Mr. Sullivan continued, "Chuck is a highly-experienced senior executive with a proven track record of leading complex manufacturing and logistics operations, focusing on efficiency, quality and customer service. He adds valuable expertise to Insulet as we continue to strengthen and scale our operations, focus on customer satisfaction and deliver the best products in the industry. These two appointments represent one of many steps we are taking across the organization to achieve operational excellence and to ensure we reach profitability in the near-term."
About Shacey Petrovic:
Shacey Petrovic is a seasoned expert with nearly two decades of experience in the medical device industry. She most recently served as Insulet's Chief Commercial Officer and prior to joining the Company in February 2015, she was President and Chief Executive Officer of Clinical Innovations, a developer and manufacturer of medical devices and diagnostics for women's health. Ms. Petrovic has a long track record of success within commercial operations, including new product introduction, market share growth and business development. Prior to Clinical Innovations, Ms. Petrovic served in a number of key roles during her 13 years with Hologic and Cytyc, including Vice President and General Manager of the company's GYN Surgical Products Division. During her tenure, Ms. Petrovic also held various sales and marketing leadership roles in the U.S. and Europe. Previously, Ms. Petrovic served as an award-winning Pharmaceutical Sales Specialist at AstraZeneca. She earned her B.S. in Biology from the University of Wisconsin.
About Charles Alpuche:
Mr. Alpuche brings more than 30 years of manufacturing, operations and engineering experience, having served in roles of increasing responsibility and leadership throughout his career, most of which was at PepsiCo. Most recently, Mr. Alpuche served as an independent consultant for both domestic and international companies in the food, beverage and chemical industries. Prior to retiring from PepsiCo, Mr. Alpuche served most recently as Senior Vice President of North America Beverages, where he led all bottling manufacturing and logistics operations, was Vice President and General Manager Concentrate Operations Asia and Americas, and held other leadership roles overseeing domestic and international plant operations. Mr. Alpuche holds a B.S. in Business Administration from Delaware Valley College and obtained an Executive M.S. in Organizational Management from the University of Pennsylvania.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 29, 2016 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
Investor Relations and Media Contact:
Deborah R. Gordon Vice President, Investor Relations and Corporate Communications (978) 600-7717 firstname.lastname@example.org
SOURCE Insulet Corporation